3 results
Approved WMORecruiting
The purpose of this study is to allow collection of safety and tolerability data in subjects benefitting from treatment with spartalizumab as a single agent or in combination with other study treatments in a pre-defined (Appendix Section 16.1)…
Approved WMOCompleted
To perform a patient satisfaction study on the Equil patch pump in T1DM patients that currently already use CSII in combination with CGM or Flash glucose monitoring.
Approved WMOCompleted
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)